North Carolina Headlines

(Albany, New tork) – September 10 2026: DelveInsight’s report “Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Prostate Cancer landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Prostate Cancer market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prostate Cancer Market Forecast

Some of the key facts of the Prostate Cancer Market Report:

• In 2023, the Prostate Cancer Treatment market size across the 7 major markets (7MM) was valued at approximately USD 12,300 million and is expected to grow by 2034.

• The United States accounted for the largest share of this market within the 7MM during the same year. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Prostate Cancer landscape.

• In 2023, Germany led the Prostate Cancer Diagnostics market within the EU4 and UK, whereas Spain reported the smallest market share during the same period. In the US, 2nd Generation ADTs accounted for the largest segment of the Prostate Cancer Diagnostics market in 2023, with an estimated value of around USD 4,350 million.

• In 2023, the 7 major markets (7MM) had an estimated 7,279,500 prevalent prostate cancer cases, a figure expected to rise between 2024 and 2034 due to an aging population and advancements in diagnostic technologies. In the US, the five-year prevalence of prostate cancer cases was around 1,093,300 in 2023.

• Within the EU4 and UK, Germany reported the highest number of metastatic CRPC cases, while Spain had the lowest. In the US, the majority of prostate cancer cases were localized or locally advanced (Stage I–III), accounting for approximately 56% of cases, about 33% were biochemical recurrence or progressive cases, and roughly 11% were metastatic. Of all metastatic cases, around 43% were classified as mCRPC, with the remaining 57% being mCSPC.

• According to DelveInsight’s estimates, the total prevalent prostate cancer cases in the 7MM reached approximately 8,241,400 in 2023, though this figure does not reflect the treatable population. These cases are projected to increase throughout the forecast period from 2024 to 2034.

• In 2023, the United States reported the highest prevalence, with around 3,803,500 cases. Most cases in the US were diagnosed in individuals aged 65 to 74, accounting for nearly 40% of the total. Locally advanced stages (Stage I–III) represented the largest share of diagnosed prevalent cases in 2023, exceeding 903,700 cases, followed by biochemical recurrence/progression and metastatic cases.

• In August 2026, A newly approved treatment option for metastatic prostate cancer is now available to a significantly broader patient population. The U.S. Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (177Lu-PSMA-617) for use alongside hormonal therapy as a first-line treatment for patients with metastatic prostate cancer whose PET scans confirm the presence of PSMA-positive tumors. This expanded indication substantially increases the number of patients who may be eligible to receive the targeted radioligand therapy.

• In December 2025, Arteus Technologies announced that the first patient has been dosed in a phase 1 clinical trial evaluating ART-101 in individuals with metastatic castration-resistant prostate cancer (mCRPC). ART-101 is described as a novel receptor-targeting small molecule designed for both imaging and treating prostate cancer. In preclinical studies, the therapy showed greater tumor uptake and retention and reduced absorption in healthy tissues and salivary glands compared with currently approved PSMA-targeted radioligand treatments.

• In December 2025, Telix Pharmaceuticals (ASX: TLX) announced that the first patient has been treated in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial, advancing its efforts to develop innovative radiopharmaceutical therapies for advanced prostate cancer. The initial dosing took place at the Australian Prostate Centre in Melbourne, officially launching Part 2 of the study. This phase will enroll approximately 490 patients across Australia, New Zealand, and Canada, with plans for broader global participation. The trial is assessing TLX591, Telix’s PSMA-targeted radio antibody drug conjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).

• In November 2025, Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based, science-driven biotechnology company dedicated to developing and commercializing innovative plant-derived therapies for urinary system diseases, primarily targeting the U.S., EU, and Asian markets, announced a significant milestone in the development of its drug MCS-8 (PCP). The company has completed the statistical analysis of the primary efficacy endpoints from its ongoing Phase II clinical trial in Taiwan, which enrolled over 700 high-risk subjects in a randomized, placebo-controlled design. The results showed that, compared with placebo, MCS-8 (PCP) led to lower incidence rates of prostate cancer and high-grade prostate cancer (Gleason Score ≥7), while demonstrating good overall tolerability. These findings provide a strong foundation for potential future multinational Phase III trials.

• In September 2025, Shanghai Henlius Biotech and Organon announced that the U.S. FDA has approved BILDYOS® (denosumab-nxxp) 60 mg/mL and BILPREVDA® (denosumab-nxxp) 120 mg/1.7 mL, biosimilars of PROLIA® and XGEVA®, respectively, for all indications of the reference products. BILDYOS is a RANK ligand (RANKL) inhibitor indicated for treating osteoporosis in high-risk postmenopausal women and men, glucocorticoid-induced osteoporosis, and for increasing bone mass in prostate and breast cancer patients undergoing specific therapies. Patients with advanced kidney disease are at increased risk of severe hypocalcemia, requiring careful monitoring before and during treatment.

• In August 2025, Lantheus Holdings announced that the FDA has accepted the New Drug Application (NDA) for a new formulation of its F-18 PSMA imaging agent, submitted by its affiliate Aphelion. The FDA’s action date is scheduled for March 6, 2026. This new formulation is designed to achieve comparable efficacy to Lantheus’ leading PSMA PET agent, PYLARIFY, which demonstrates a median true-positive rate of 86% in detecting recurrent prostate cancer.

• In August 2025, Atavistik Bio has dosed the first patient in a Phase 1 trial of ATV-1601, a selective inhibitor targeting the AKT1 E17K mutation in solid tumors, including breast, endometrial, and prostate cancers. The therapy employs a reversible allosteric mechanism and has demonstrated improved efficacy and tolerability compared to broader AKT inhibitors in preclinical studies.

• In July 2025, Telix announced that its prostate cancer PET imaging agent, Illuccix® (gallium-68 gozetotide), has received marketing authorization from BASG in Austria. The approval permits the detection and localization of PSMA-positive lesions in adults with prostate cancer, enabling broader utilization of PSMA-PET imaging with this validated gallium-based radiopharmaceutical.

• In July 2025, Artera has been granted FDA Breakthrough Device Designation for ArteraAI Prostate, an AI-driven tool developed to assist clinicians in making risk-based treatment decisions for patients with localized prostate cancer.

• In June 2025, Siemens Healthineers Molecular Imaging has partnered with Massachusetts General Hospital to advance theranostics, leveraging radiopharmaceuticals for both diagnosis and therapy, particularly in cancers such as thyroid, prostate, and neuroendocrine tumors. Molecular imaging supports the evaluation of disease progression and treatment response.

• In June 2025, Telix announced that its prostate cancer PET imaging agent, Illuccix® (kit for preparing gallium-68 gozetotide injection) has received marketing authorization in Greece (EOF), Belgium (AFMPS), and Italy (AIFA). The approval covers the detection and localization of PSMA-positive lesions in adults with prostate cancer, giving healthcare providers in these countries access to a clinically validated gallium-based radiopharmaceutical for PSMA-PET imaging and broadening diagnostic options for patients.

• Key Prostate Cancer Companies: Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen Research & Development/Tesaro, Sanofi, MacroGenics, Candel Therapeutics, Kangpu Biopharmaceuticals, Point Biopharma, AstraZeneca, Essa Pharma, and others

• Key Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), XTANDI (enzalutamide), AKEEGA (niraparib + abiraterone acetate + prednisone), JEVTANA + prednisone, MGC018 (vobramitamab duocarmazine), CAN-2409, KPG-121, 177Lu-PNT2002 (PNT2002), Capivasertib, CAN-2409 + valacyclovir + radiation therapy ± ADT, MGC018, EPI-7386, and others

• The Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prostate Cancer pipeline products will significantly revolutionize the Prostate Cancer market dynamics.

Prostate Cancer Overview

Prostate cancer is a type of cancer that develops in the prostate gland, a small gland in men that produces seminal fluid. It is one of the most common cancers in men, especially those over 50. Prostate cancer often grows slowly and may initially cause no symptoms, but advanced stages can lead to difficulty urinating, blood in urine, and pelvic pain. Risk factors include age, family history, and genetic mutations. Treatment options vary based on stage and may include surgery, radiation therapy, hormone therapy, chemotherapy, or active surveillance.

Get a Free sample for the Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/prostate-cancer-market-insight

Prostate Cancer Epidemiology

The Prostate Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prostate Cancer Epidemiology Segmentation:

The Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Prostate Cancer

• Prevalent Cases of Prostate Cancer by severity

• Gender-specific Prevalence of Prostate Cancer

• Diagnosed Cases of Episodic and Chronic Prostate Cancer

Download the report to understand which factors are driving Prostate Cancer epidemiology trends @ Prostate Cancer Epidemiology Forecast

Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prostate Cancer market or expected to get launched during the study period. The analysis covers Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prostate Cancer Pipeline Development Activities.

It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prostate Cancer Therapies and Key Companies

• NUBEQA (darolutamide): Bayer

• ERLEADA (apalutamide): Johnson & Johnson Innovative Medicine (Janssen)

• XTANDI (enzalutamide): Astellas Pharma/Pfizer

• AKEEGA (niraparib + abiraterone acetate + prednisone): Janssen Research & Development/Tesaro

• JEVTANA + prednisone: Sanofi

• MGC018 (vobramitamab duocarmazine): MacroGenics

• CAN-2409: Candel Therapeutics

• KPG-121: Kangpu Biopharmaceuticals

• 177Lu-PNT2002 (PNT2002): Point Biopharma

• Capivasertib: AstraZeneca

• CAN-2409 + valacyclovir + radiation therapy ± ADT: Candel Therapeutics

• MGC018: MacroGenics

• EPI-7386: Essa Pharma

Discover more about therapies set to grab major Prostate Cancer market share @ Prostate Cancer Treatment Landscape

Prostate Cancer Market Drivers

• Rising Incidence Rates

• Advancements in Treatment Options

• Increased Awareness and Screening

• Government Initiatives

• Innovative Diagnostic Techniques

Prostate Cancer Market Barriers

• High Treatment Costs

• Regulatory Challenges

• Limited Awareness in Certain Populations

• Adverse Effects of Treatments

• Competition from Alternative Therapies

Scope of the Prostate Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Prostate Cancer Companies: Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen Research & Development/Tesaro, Sanofi, MacroGenics, Candel Therapeutics, Kangpu Biopharmaceuticals, Point Biopharma, AstraZeneca, Essa Pharma, and others

• Key Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), XTANDI (enzalutamide), AKEEGA (niraparib + abiraterone acetate + prednisone), JEVTANA + prednisone, MGC018 (vobramitamab duocarmazine), CAN-2409, KPG-121, 177Lu-PNT2002 (PNT2002), Capivasertib, CAN-2409 + valacyclovir + radiation therapy ± ADT, MGC018, EPI-7386, and others

• Prostate Cancer Therapeutic Assessment: Prostate Cancer current marketed and Prostate Cancer emerging therapies

• Prostate Cancer Market Dynamics: Prostate Cancer market drivers and Prostate Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Prostate Cancer Market Access and Reimbursement

To know more about Prostate Cancer companies working in the treatment market, visit @ Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Prostate Cancer Market Report Introduction

2. Executive Summary for Prostate Cancer

3. SWOT analysis of Prostate Cancer

4. Prostate Cancer Patient Share (%) Overview at a Glance

5. Prostate Cancer Market Overview at a Glance

6. Prostate Cancer Disease Background and Overview

7. Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Prostate Cancer

9. Prostate Cancer Current Treatment and Medical Practices

10. Prostate Cancer Unmet Needs

11. Prostate Cancer Emerging Therapies

12. Prostate Cancer Market Outlook

13. Country-Wise Prostate Cancer Market Analysis (2020–2034)

14. Prostate Cancer Market Access and Reimbursement of Therapies

15. Prostate Cancer Market Drivers

16. Prostate Cancer Market Barriers

17. Prostate Cancer Appendix

18. Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/